ENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands

Zacks2024-10-30

Enzo Biochem, Inc. ENZ delivered a loss per share of 19 cents from continuing operations in fiscal 2024, narrower than the loss of 51 cents per share in the comparable fiscal 2023 period. Enzo Biochem...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479305867?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/E6c.Br4zGaRkJms.T3VV6g--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/720c8da91f84eaf3696b8496766072f1","is_english":true,"pubTime":"2024-10-30 23:47","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2479305867","market":"us","top_or_hot":-1,"title":"ENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands","media":"Zacks","content":"<div>\n<p>Enzo Biochem, Inc. ENZ delivered a loss per share of 19 cents from continuing operations in fiscal 2024, narrower than the loss of 51 cents per share in the comparable fiscal 2023 period.\nEnzo Biochem...</p>\n\n<a href=\"https://finance.yahoo.com/news/enz-stock-following-fy24-earnings-154700181.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-30 23:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/enz-stock-following-fy24-earnings-154700181.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Enzo Biochem, Inc. ENZ delivered a loss per share of 19 cents from continuing operations in fiscal 2024, narrower than the loss of 51 cents per share in the comparable fiscal 2023 period.\nEnzo Biochem...</p>\n\n<a href=\"https://finance.yahoo.com/news/enz-stock-following-fy24-earnings-154700181.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ENZ","symbol_name":"恩佐生化","start_time":0,"source_url":"https://finance.yahoo.com/news/enz-stock-following-fy24-earnings-154700181.html","article_id":"2479305867","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/E6c.Br4zGaRkJms.T3VV6g--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/720c8da91f84eaf3696b8496766072f1"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479305867","pubTimestamp":1730303220,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Enzo Biochem, Inc. ENZ delivered a loss per share of 19 cents from continuing operations in fiscal 2024, narrower than the loss of 51 cents per share in the comparable fiscal 2023 period.Enzo Biochem’s Life Sciences Products reporting unit operates in one reportable segment, Products.The company’s Products revenues were $7.5 million in the fiscal fourth quarter, down 16% year over year. This was due to a shift in ordering patterns.The company’s Products revenues were $31.9 million in fiscal 2024, up 2.7% from the comparable fiscal 2023 period. This was driven by an increase in the marketing effort in drug development and cell and gene therapy markets.Enzo Biochem’s operations consist of three geographic regions — the United States, Europe and Asia Pacific.Revenues in the Europe segment totaled $8.6 million, up 1.3% from the comparable fiscal 2023 period, while the Asia Pacific segment generated revenues of $3.9 million, down 5% from the comparable fiscal 2023 period.Cumulative net cash","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ENZ":"恩佐生化"},"translate_title":"ENZ股价在2024财年盈利上升后上涨，毛利率扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENZ":1},"content_text":"Enzo Biochem, Inc. ENZ delivered a loss per share of 19 cents from continuing operations in fiscal 2024, narrower than the loss of 51 cents per share in the comparable fiscal 2023 period.\nEnzo Biochem’s Revenues in Detail\nEnzo Biochem’s Life Sciences Products reporting unit operates in one reportable segment, Products.\nThe company’s Products revenues were $7.5 million in the fiscal fourth quarter, down 16% year over year. This was due to a shift in ordering patterns.\nThe company’s Products revenues were $31.9 million in fiscal 2024, up 2.7% from the comparable fiscal 2023 period. This was driven by an increase in the marketing effort in drug development and cell and gene therapy markets.\nShares of this company gained 2.7% in pre-market trading.\nFind the latest EPS estimates and surprises on Zacks Earnings Calendar.\nENZ’s Geographic Details\nEnzo Biochem’s operations consist of three geographic regions — the United States, Europe and Asia Pacific.\nFor fiscal 2024, the United States reported revenues of $19.5 million, up 5.1% from the comparable fiscal 2023 period.\nRevenues in the Europe segment totaled $8.6 million, up 1.3% from the comparable fiscal 2023 period, while the Asia Pacific segment generated revenues of $3.9 million, down 5% from the comparable fiscal 2023 period.\n\nEnzo Biochem, Inc. Price, Consensus and EPS Surprise\n  \nEnzo Biochem, Inc. price-consensus-eps-surprise-chart | Enzo Biochem, Inc. Quote\n\nEnzo Biochem’s Gross Margin\nFor the fiscal fourth quarter, Enzo Biochem’s gross margin was 43% compared with the year-ago quarter’s 35%. The 800-basis point improvement was driven by the non-repeating nature of the inventory provision, the mix of products sold and ongoing cost containment initiatives.\nFor fiscal 2024, the gross margin was 45.9% compared with 42.5% in the comparable fiscal 2023 period. Fiscal 2024 gross profit was positively impacted by the more profitable mix of the types of products sold, higher revenues sourced from the U.S. market and lower input costs.\nENZ’s Operating Expenses Analysis\nSelling, general and administrative expenses for fiscal 2024 decreased 20.1% to $21.7 million. Research and development expenses decreased 32.3% from the comparable fiscal 2023 period to $2.6 million.\nEnzo Biochem’s Profitability\nThe operating loss for fiscal 2024 totaled $12.4 million, narrower than the prior-fiscal year’s operating loss of $24.7 million.\nEnzo Biochem’s adjusted EBITDA for fiscal 2024 was a loss of $6.5 million.\nFor fiscal 2024, Enzo Biochem’s net loss from continuing operations was $9.8 million, narrower than the prior-fiscal year’s net loss of $25 million.\nENZ’s Liquidity & Debt Management\nEnzo Biochem exited fiscal 2024 with cash and cash equivalents of $52.4 million compared with $82.4 million at fiscal 2023-end.\nTotal long-term debt at fiscal 2024-end was $0.2 million compared with $0.3 million at the end of fiscal 2023.\nCumulative net cash used in operating activities at the end of fiscal 2024 was $26.3 million compared with $36.9 million a year ago.\nOur Take\nEnzo Biochem exited fiscal 2024 with encouraging top-line and bottom-line results. Robust performances by the majority of its geographic regions were impressive. The expansion of gross margin bodes well.\nHowever, Enzo Biochem’s continued loss per share in the reported quarter was disappointing. The decline in the revenues from the Asia Pacific region was discouraging.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nEnzo Biochem, Inc. (ENZ) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479305867"}